This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a retrospective comparative study with historical controls that was based around a change in hospital policy in May 1999. It was undertaken in a single NSU in Cleveland (OH), USA. Glasgow Outcome Scale (GOS) scores were obtained either from outpatient records or via telephone interviews 3 months after discharge. Eleven patients (5 in group 1 and 6 in group 2) were lost to follow-up and were assigned the worst possible outcome score.
Analysis of effectiveness
The analysis of effectiveness was carried out on all patients included in the study (i.e. 140 patients). The primary outcome measure used was the GOS. For statistical analysis, the GOS was dichotomised as a good outcome (scores 4 -5) or poor outcome (scores 1 -3). A logistic regression analysis was used to identify goods outcome at 3 months (based on the GOS), and these were adjusted for age, gender, race and the Glasgow Coma Scale (GCS). Group 1 (prior to May 1999) was compared with group 2 (after June 1999). An additional sub-group analysis comparing just those patients who received human albumin (n=37) and those who received extra boluses of normal saline (n=47) was also undertaken.
Effectiveness results
The results of the initial group analysis (before and after May 1999) were as follows.
GCS score less than 8: 22% (group 1) versus 31% (group 2);,(p=0.2).
Baseline central venous pressure: 5.2 mmHg (group 2) versus 4.8 mmHg, (p=0.6).
Symptomatic vasospasm: 13% (group 1) versus 18% (group 2), (p=0.3).
Logistic regression (adjusted for age, gender, race and GCS less than 8) found that the administration of human albumin was not a predicator of in-hospital death or poor clinical outcome at 3 months after discharge.
The results of the sub-group analysis were presented in full in the paper.
Clinical conclusions
The administration of human albumin was not found to be harmful for this patient population. It was an independent predictor of better outcomes at 3 months after SAH. It was not found to have an effect on in-hospital death.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was produced. In effect, a costconsequences analysis was performed.
Direct costs
The direct costs included in the analysis were the total hospital, laboratory and radiological costs. The resource use quantities and the unit cost were reported separately in so far as days in hospital and days in the NSU were presented, as well as the total hospital, laboratory and radiological costs. Full details of the costings were not provided, but they appear to have been based on actual data and costs, as recorded in patient medical reports. The data pertained to the years 1998 to 2000 and were corrected for inflation, although further details of this were not given. Discounting was not relevant because of the short timeframe of the analysis. The price year was not reported.
Statistical analysis of costs
Descriptive statistics including means and standard deviations were reported for each group. A Kolmogorov-Smirnov test for normality and an equal variances test were undertaken before further statistical analysis. The resource use and cost data were analysed using two-tailed t-tests.
